How can pharmacogenomics biomarkers be translated into patient benefit [Conference Abstract]

Collier, D., Achilla, E., Breen, G., Curran, S., Dima, D., Flanagan, R., Frank, J., Frangou, S., Gasse, C., Giegling, I., Rietschel, M., Rujescu, D., Maccabe, J., McCrone, P., Mill, J., Sigurdsson, E., Stefansson, H., Walters, James Tynan Rhys ORCID: https://orcid.org/0000-0002-6980-4053, Verbelen, M. and Helthuis, M. 2015. How can pharmacogenomics biomarkers be translated into patient benefit [Conference Abstract]. European Psychiatry 30 (Suppl1) , p. 94. 10.1016/S0924-9338(15)30078-X

Full text not available from this repository.

Abstract

Treatment resistant schizophrenia (TRS) is one of the most disabling of psychiatric disorders, affecting about 1/3 of patients. First-line treatments include both atypical and typical antipsychotics. The original atypical, clozapine, is a final option, and although it has been shown to be the only effective treatment for TRS, many patients do not respond well to clozapine. Clozapine use is related to adverse events, most notably agranulocytosis, a potentially fatal blood disorder which affects about 1% of those prescribed clozapine and requires regular blood monitoring. This as a barrier to prescription and there is a long delay in access for TRS patients, of five or more years, from first antipsychotic prescription. Better tools to predict treatment resistance and to identify risk of adverse events would allow faster and safer access to clozapine for patients who are likely to benefit from it. The CRESTAR project (www.crestar-project.eu) is a European Framework 7 collaborative project that aims to develop tools to predict i) treatment response, particularly patients who are less likely to respond to usual antipsychotics, indicating treatment with clozapine as early as possible, ii) patients who are at high or low risk of adverse events and side effects, iii) extreme TRS patients so that they can be stratified in clinical trials for novel treatments. CRESTAR has addressed these questions by examining genome-wide association data, genome sequence, epigenetic biomarkers and epidemiological data in European patient cohorts characterized for treatment response, and adverse drug reaction using data from clozapine therapeutic drug monitoring and linked National population medical and pharmacy databases, to identify predictive factors. In parallel CRESTAR will perform health economic research on potential benefits, and ethics and patient-centred research with stakeholders.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) Neuroscience and Mental Health Research Institute (NMHRI)
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Publisher:	Elsevier
ISSN:	0924-9338
Last Modified:	31 Oct 2022 10:57
URI:	https://orca.cardiff.ac.uk/id/eprint/86791

Actions (repository staff only)

Edit Item